Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy

Arjun Gupta; Samar Harris; Steven Vernino; Harris V Naina

doi:10.1007/s10286-015-0299-5

Rituximab-based therapy and long-term control of autoimmune autonomic ganglionopathy

Clin Auton Res. 2015 Aug;25(4):255-8. doi: 10.1007/s10286-015-0299-5. Epub 2015 Aug 7.

Authors

Arjun Gupta¹, Samar Harris², Steven Vernino³, Harris V Naina⁴

Affiliations

¹ Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. guptaarjun90@gmail.com.
² Department of Gastroenterology and Hepatology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
³ Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, TX, USA.
⁴ Department of Hematology, University of Texas Southwestern Medical Center, Seay Biomedical Building, 2201 Inwood Road, Dallas, TX, 75390-8562, USA. Harris.Naina@UTSouthwestern.edu.

PMID: 26245264
DOI: 10.1007/s10286-015-0299-5

Abstract

We present a patient with autoimmune autonomic ganglionopathy (AAG) who had persistently positive ganglionic nicotinic acetylcholine receptor antibody levels despite immunosuppressive therapy. Rituximab-based therapy for an incidental lymphoma was associated with prolonged symptomatic and serological control of AAG.

Keywords: Autoimmune autonomic ganglionopathy; Management; Rituximab.

Publication types

Case Reports

MeSH terms

Autoimmune Diseases of the Nervous System / diagnosis*
Autoimmune Diseases of the Nervous System / drug therapy*
Ganglia, Autonomic / pathology*
Humans
Immunologic Factors / therapeutic use*
Male
Middle Aged
Rituximab / therapeutic use*

Substances

Immunologic Factors
Rituximab